Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Durvalumab by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Durvalumab by AstraZeneca for Leiomyosarcoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...
Durvalumab by AstraZeneca for Melanoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...
Durvalumab by AstraZeneca for Angiosarcoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II drugs...
Durvalumab by AstraZeneca for Metastatic Melanoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Pancreatic Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...
Durvalumab by AstraZeneca for Salivary Gland Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase...
Durvalumab by AstraZeneca for Neuroendocrine Carcinoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Germ Cell Tumors: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Germ Cell Tumors. According to GlobalData, Phase...
Durvalumab by AstraZeneca for Vulvar Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Vaginal Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Anal Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Anal Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Pancreatic Cancer: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...